STOCK TITAN

Amicus Therapeutics, Inc - FOLD STOCK NEWS

Welcome to our dedicated page for Amicus Therapeutics news (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeutics stock.

Amicus Therapeutics, Inc. (symbol: FOLD) is a global biotechnology company that specializes in discovering, developing, and delivering high-quality medicines for individuals suffering from rare metabolic diseases. The company's central focus revolves around addressing lysosomal storage disorders, such as Fabry disease and Pompe disease, through its innovative platform technologies and medicines.

Amicus Therapeutics operates with a patient-centric approach, ensuring that the needs of those in the rare disease community are at the forefront of their scientific research, commercial activities, and clinical programs. The company is dedicated to creating significant impacts on the lives of patients and their caregivers, striving to provide advanced therapeutic solutions where none previously existed.

The company's product pipeline includes:

  • Galafold® (migalastat): An oral chaperone therapy approved for the treatment of adults with Fabry disease who have amenable genetic variants. Galafold works by stabilizing the body’s own dysfunctional enzyme to clear the accumulated substrate.
  • Pombiliti™ and Opfolda™: A novel, two-component therapy designed for the treatment of late-onset Pompe disease, showcasing Amicus's commitment to addressing the complexities of metabolic disorders.
  • Rare Disease Gene Therapy Portfolio: A set of advanced gene therapies aimed at providing long-lasting solutions for various rare metabolic diseases.

Amicus Therapeutics is focused on expanding its pipeline with first-in-class or best-in-class treatments, underscoring its commitment to innovative medical solutions. Financially, the company maintains a strong position, actively pursuing strategic priorities to sustain growth and enhance shareholder value.

With a presence in 27 countries, Amicus Therapeutics leverages a global footprint to address unmet medical needs across diverse patient populations. The company continuously seeks opportunities to broaden its impact and foster collaborations that advance its mission.

Recent developments include regulatory approvals and strategic partnerships aiming to enhance the reach and effectiveness of their therapies. By building strong relationships with stakeholders, Amicus Therapeutics ensures a collaborative effort in combating rare diseases.

Overall, Amicus Therapeutics Inc. embodies a profound dedication to transforming the lives of those affected by rare diseases through innovative science, patient-focused care, and robust therapeutic development.

Rhea-AI Summary

PHILADELPHIA, Feb. 08, 2023 - Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 10:40 a.m. E.T. The event will be held virtually.

Investors can access the live audio webcast through the company’s investors section on their website. Amicus Therapeutics focuses on developing high-quality medicines for rare diseases, emphasizing patient care and innovative solutions. The company is committed to advancing its pipeline, aiming for first- or best-in-class treatments for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
-
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) reported 2022 revenue of approximately $329 million, reflecting a 16% year-over-year growth at constant exchange rates (CER). The company expects continued growth in 2023, forecasting 12-17% revenue growth for Galafold, driven by increased demand and geographic expansion. The company is also on track for multiple approvals for AT-GAA in Pompe disease and aims for non-GAAP profitability in the second half of 2023. Notably, over 2,000 patients are currently using Galafold.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) will have its President and CEO, Bradley Campbell, present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PT in San Francisco, CA. Investors can access a live audio webcast of the presentation via the company's website. Amicus Therapeutics focuses on developing innovative treatments for rare diseases, showcasing a commitment to high-quality medicine delivery for patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for cipaglucosidase alfa, an enzyme replacement therapy for adults with late-onset Pompe disease. The decision from the European Commission is anticipated in Q1 2023. Cipaglucosidase alfa, part of the two-component therapy AT-GAA, is designed to address unmet medical needs in this patient population. The CHMP's recommendation was based on robust clinical data, including a pivotal Phase 3 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Stifel 2022 Healthcare Conference on November 16, 2022, at 9:45 a.m. E.T., held in New York, NY. Investors can access a live audio webcast of the presentation through the investors section of the Amicus corporate website. The company is dedicated to developing innovative medicines for rare diseases, emphasizing a strong commitment to patient care and a robust pipeline of first- or best-in-class treatments. For more details, visit the Amicus website or follow them on social media.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences
-
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced an update regarding its investigational therapy AT-GAA. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has altered its agenda for its November meeting, indicating that oral explanations for miglustat and cipaglucosidase alfa will not occur as previously expected on November 9. Despite this setback, Amicus remains focused on preparing for a potential CHMP opinion on AT-GAA by December 2022 and will evaluate any changes to the anticipated timelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) reported a 3% increase in Q3 2022 revenue, totaling $81.7 million, with operational growth at 14% at constant exchange rates. Year-to-date revenue grew by 8% and is on track for 15-20% growth for the full year. Non-GAAP operating expenses guidance has been updated to $430-$440 million, down from $470-$485 million. The company anticipates non-GAAP profitability in H2 2023. Regulatory reviews for AT-GAA for Pompe disease are progressing, with an EU opinion expected in December 2022, while FDA actions are deferred due to inspection delays.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
-
Rhea-AI Summary

The FDA has issued a deferred action letter regarding Amicus Therapeutics' Biologics License Application for cipaglucosidase alfa, a key component of AT-GAA, due to COVID-19 travel restrictions preventing a required manufacturing site inspection. The company is committed to working with the FDA to finalize plans for this inspection. The FDA has not provided any anticipated action dates while monitoring the public health situation. Despite this setback, Amicus remains optimistic about the approval timeline for AT-GAA and is also pleased with the progress of its review in the EU, expecting a CHMP opinion by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
none
-
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced a conference call on November 7, 2022, at 8:30 a.m. ET, to discuss its third-quarter financial results for the period ending September 30, 2022. Interested participants can register online for phone access and a live audio webcast will also be available via the company’s investor relations page. An archived version of the webcast and presentation materials will be uploaded on the company's website after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced that four poster presentations showcasing its Pompe disease development program will be presented at the 27th International Hybrid Annual Congress of the World Muscle Society from October 11-15, 2022, in Halifax, Canada. The presentations include long-term studies and patient surveys highlighting the impacts of Pompe disease. Notable abstracts focus on treatment comparisons and patient experiences during the COVID-19 pandemic. The posters will be accessible on Amicus's website following the congress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.24%
Tags
none

FAQ

What is the current stock price of Amicus Therapeutics (FOLD)?

The current stock price of Amicus Therapeutics (FOLD) is $9.8 as of December 20, 2024.

What is the market cap of Amicus Therapeutics (FOLD)?

The market cap of Amicus Therapeutics (FOLD) is approximately 2.9B.

What does Amicus Therapeutics, Inc. specialize in?

Amicus Therapeutics specializes in discovering, developing, and delivering medicines for rare metabolic diseases such as Fabry disease and Pompe disease.

What is Galafold?

Galafold (migalastat) is an oral therapy for treating adults with Fabry disease who have amenable genetic variants. It stabilizes the body's dysfunctional enzyme to clear accumulated substrate.

What are Pombiliti and Opfolda?

Pombiliti and Opfolda are a novel, two-component therapy designed for the treatment of late-onset Pompe disease, aiming to address the complexities of this metabolic disorder.

What makes Amicus Therapeutics unique?

Amicus Therapeutics is unique for its patient-centric approach, focusing on innovative solutions for rare diseases, and maintaining a robust pipeline of first- or best-in-class medicines.

How large is the footprint of Amicus Therapeutics?

Amicus Therapeutics has a global presence, operating in 27 countries to address unmet medical needs in diverse patient populations.

What is the company's approach to patient care?

Amicus Therapeutics places the needs of the rare disease community at the center of its scientific research, clinical programs, and commercial activities to improve patient lives significantly.

What recent achievements has Amicus Therapeutics made?

Recent achievements include regulatory approvals for therapies like Galafold and strategic partnerships aimed at enhancing their therapeutic reach and effectiveness.

What is included in Amicus Therapeutics' gene therapy portfolio?

The gene therapy portfolio consists of advanced gene therapies designed to provide long-lasting solutions for various rare metabolic diseases.

How does Amicus Therapeutics ensure its financial health?

The company focuses on strategic priorities, partnerships, and a robust pipeline to maintain strong financial health and sustain growth.

How can one report adverse reactions to Amicus Therapeutics' products?

Adverse reactions can be reported by contacting Amicus Therapeutics at 1-877-4AMICUS or the FDA at 1-800-FDA-1088.

Amicus Therapeutics, Inc

Nasdaq:FOLD

FOLD Rankings

FOLD Stock Data

2.89B
267.94M
0.74%
105.23%
7.03%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON